Biodesix Targeting Pharma for VeriStrat Adoption, Growth | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – As Biodesix continues clinical validation and commercialization of its test to predict patient response to therapies for non-small cell lung cancer, it is looking to forge pharmaceutical partnerships to increase adoption of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.